Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. The company is headquartered in Lexington, Massachusetts and currently employs 316 full-time employees. The company went IPO on 2000-02-04. The Company’s pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is immuno-oncology (I-O), and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody) and balstilimab (a novel, fully human monoclonal immunoglobulin G4 (IgG4) PD-1 inhibitor). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
Follow-Up Questions
Qui est le CEO de Agenus Inc ?
Dr. Garo Armen est le Chairman of the Board de Agenus Inc, il a rejoint l'entreprise depuis 1994.
Quelle est la performance du prix de l'action AGEN ?
Le prix actuel de AGEN est de $4.41, il a decreased de 3.07% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Agenus Inc ?
Agenus Inc appartient à l'industrie Biotechnology et le secteur est Health Care
Quelle est la capitalisation boursière de Agenus Inc ?
La capitalisation boursière actuelle de Agenus Inc est de $140.5M
Est-ce que Agenus Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 5 analystes ont établi des notations d'analystes pour Agenus Inc, y compris 2 achat fort, 5 achat, 2 maintien, 0 vente et 2 vente forte
